Please give us a background on your clinical practice

The patients that are being put on Nurtec ODT, are they exclusively after 2 failures per the label? Unless they have vascular disease where they can't be put on a triptan? And what % of patients do you estimate that would be?

What is payer access like? I hear that United Healthcare is a nightmare to deal with, can you talk about the obstacles there a bit? How about at other payers? How has the situation been with Medicare? I hear it Nurtec ODT is basically not an option for low-income patients?

From my understanding Biohaven has done a really great job getting onto the formularies and has a copay card that allows patients to renew for 6 months. How big of a factor do you think that is for uptake in the acute treatment setting?

Do you think the social media/celebrity presence has had a meaningful impact? Do your patients ever bring up that they heard of the drug because one of the Kardashians uses it or anything like that?

So now that Qulipta has been on the market for a few months now, can you compare and contrast coverage between Nurtec and Qulipta in the preventative settings? From my understanding it is very difficult go get Nurtec for preventative use?

Let's talk about more of the clinical side. How do you feel patient experience has been with Nurtec, both from an abortive and preventative context?

From talking to other doctors, it seems like the best case scenario is for patients who have a slow onset to peak intensity, since that is the big weakness of Nurtec and Ubrelvy. And from my understanding there is 8 ODTs in a box for abortive, and 15 for preventative. Given that most people use it for an abortive context, do you think some of those patients use the ODTs fairly liberally given that there isn't a risk of analgesic rebound, no side effects, etc.

Do you ever use gepants in combination with the mabs? I've heard some docs will prescribe nurtec and will instruct them to take it every other day starting the week before the next mAB injection, then they have 4 or 5 ODTs left over for abortive use. Is that a common practice?

How difficult is it from to get coverage for a patient for both mABS and gepants?

Do you think Nurtec and Ubrelvy could continue to grow just by continuing to target PCPs? If it's easy to use, easy to prescribe, and easy to start due to samples, coupons or copay cards?

How have CGRPs antibodies and gepants affected your practice since their approvals?